ADC Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 193

Employees

  • Stock Symbol
  • ADCT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.28
  • (As of Friday Closing)

ADC Therapeutics General Information

Description

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Biopole
  • Route de la Corniche 3B
  • 1066 Epalinges
  • Switzerland
+41 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • Biopole
  • Route de la Corniche 3B
  • 1066 Epalinges
  • Switzerland
+41 021

ADC Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ADC Therapeutics Stock Performance

As of 20-Nov-2026, ADC Therapeutics’s stock price is $1.28. Its current market cap is $180M with 141M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.28 $1.30 $0.78 - $4.98 $180M 141M 1.54M -$0.52

ADC Therapeutics Financials Summary

As of 30-Sep-2026, ADC Therapeutics has a trailing 12-month revenue of $84.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 54,211 319,814 42,691 (53,011)
Revenue 84,873 81,357 70,837 69,558
EBITDA (36,829) (96,909) (114,921) (156,367)
Net Income (81,246) (142,623) (157,846) (240,053)
Total Assets 255,863 323,150 321,980 354,782
Total Debt 116,104 117,024 122,998 124,377
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ADC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of a
Drug Discovery
Epalinges, Switzerland
193 As of 2025

Boston, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ADC Therapeutics Competitors (74)

One of ADC Therapeutics’s 74 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
Vor Biopharma Formerly VC-backed Boston, MA
BeOne Medicines Formerly PE-Backed Beijing, China
Gyre Therapeutics Formerly VC-backed San Diego, CA
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 74 competitors. Get the full list »

ADC Therapeutics Patents

ADC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026215517-A1 Antibody-drug conjugates comprising exatecan Pending 11-Apr-2025
GB-202408679-D0 An insulation apparatus Inactive 17-Jun-2024
US-20250186604-A1 Anti-psma antibody conjugates Pending 06-Dec-2023
AU-2024394903-A1 Anti-psma antibody drug conjugates comprising exatecan Pending 06-Dec-2023
EP-4820062-A1 Anti-psma antibody drug conjugates comprising exatecan Pending 06-Dec-2023 A61K47/68037
To view ADC Therapeutics’s complete patent history, request access »

ADC Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ADC Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ADC Therapeutics‘s full profile, request access.

Request a free trial

ADC Therapeutics Investments (1)

ADC Therapeutics’s most recent deal was a Joint Venture with Overland ADCT BioPharma. The deal was made on 14-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Overland ADCT BioPharma 14-Dec-2020 Joint Venture Drug Discovery
To view ADC Therapeutics’s complete investments history, request access »

ADC Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.62 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view ADC Therapeutics’s complete esg history, request access »

ADC Therapeutics FAQs

  • When was ADC Therapeutics founded?

    ADC Therapeutics was founded in 2011.

  • Where is ADC Therapeutics headquartered?

    ADC Therapeutics is headquartered in Epalinges, Switzerland.

  • What is the size of ADC Therapeutics?

    ADC Therapeutics has 193 total employees.

  • What industry is ADC Therapeutics in?

    ADC Therapeutics’s primary industry is Drug Discovery.

  • Is ADC Therapeutics a private or public company?

    ADC Therapeutics is a Public company.

  • What is ADC Therapeutics’s stock symbol?

    The ticker symbol for ADC Therapeutics is ADCT.

  • What is the current stock price of ADC Therapeutics?

    As of 20-Nov-2026 the stock price of ADC Therapeutics is $1.28.

  • What is the current market cap of ADC Therapeutics?

    The current market capitalization of ADC Therapeutics is $180M.

  • What is ADC Therapeutics’s current revenue?

    The trailing twelve month revenue for ADC Therapeutics is $84.9M.

  • Who are ADC Therapeutics’s competitors?

    Aura Biosciences, Vor Biopharma, BeOne Medicines, Gyre Therapeutics, and Gilead are some of the 74 competitors of ADC Therapeutics.

  • What is ADC Therapeutics’s annual earnings per share (EPS)?

    ADC Therapeutics’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process